Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2-Reference-Cited by-同舟云学术

Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2

Published:2021-11 Issue: Volume:116 Page:105334
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Abou-Seri Sahar M.,Eissa Amal A.M.,Behery Mohamed G.M.,Omar Farghaly A.

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference68 articles.

1. Angiogenesis inhibitors in clinical development; where are we now and where are we going?;Eskens;Br. J. Cancer,2004

2. FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma;Kwitkowski;Oncologist,2010

3. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis;Abhinand;J. Cell Commun. Signal.,2016

4. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis;La;J. Med. Chem.,2008

5. Magnetoliposomes containing calcium ferrite nanoparticles for applications in breast cancer therapy;Pereira;Pharmaceutics.,2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel imidazo[2,1-b]thiazoles and imidazo[1,2-a]pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: Design, synthesis and biological evaluations;Bioorganic Chemistry;2024-10

2. Synthesis of New Glucose-containing 5-Arylisoxazoles and their Enzyme Inhibitory Activity;Letters in Organic Chemistry;2024-08

3. Targeting hematological malignancies with isoxazole derivatives;Drug Discovery Today;2024-08

4. Hydrazide-hydrazone/hydrazone as enabling linkers in anti-cancer drug discovery: A comprehensive review;Journal of Molecular Structure;2024-07

5. From Deep Learning to the Discovery of Promising VEGFR‐2 Inhibitors;ChemMedChem;2024-06-20